# Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel in Patients With Advanced Solid Tumors

> **NCT01907685** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 58 (actual)

## Conditions studied

- Advanced Neoplastic Disease

## Interventions

- **DRUG:** AVE8062
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT01907685
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2013-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01907685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01907685, "Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01907685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*